Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luigia Trabace

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Journal of Clinical Psychopharmacology|August 18, 2016
Involvement of the NADPH Oxidase NOX2-Derived Brain Oxidative Stress in an Unusual Fatal Case of Cocaine-Related Neurotoxicity Associated With Excited Delirium SyndromeStefania Schiavone, Irene Riezzo, Emanuela Turillazzi, et al.
Scientific Reports|August 20, 2017
The NADPH oxidase NOX2 mediates loss of parvalbumin interneurons in traumatic brain injury: human autoptic immunohistochemical evidenceStefania Schiavone, Margherita Neri, Luigia Trabace, et al.
Molecules (Basel, Switzerland)|August 7, 2021
The Therapeutic Potential of Celastrol in Central Nervous System Disorders: Highlights from In Vitro and In Vivo ApproachesStefania Schiavone, Maria Grazia Morgese, Paolo Tucci, et al.
Molecules (Basel, Switzerland)|November 8, 2019
Early Celastrol Administration Prevents Ketamine-Induced Psychotic-Like Behavioral Dysfunctions, Oxidative Stress and IL-10 Reduction in The Cerebellum of Adult MiceStefania Schiavone, Paolo Tucci, Luigia Trabace, et al.
Antioxidants & Redox Signaling|July 4, 2012
Severe life stress and oxidative stress in the brain: from animal models to human pathologyStefania Schiavone, Vincent Jaquet, Luigia Trabace, et al.
CNS Drug Reviews|June 19, 2002
CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitorLuigia Trabace, Tommaso Cassano, Antonia Loverre, et al.
International Review of Neurobiology|July 18, 2009
Developmental exposure to cannabinoids causes subtle and enduring neurofunctional alterationsPatrizia Campolongo, Viviana Trezza, Maura Palmery, et al.
Neuroscience Research|December 24, 2011
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated ratsAlex Martinez, Teresa Macheda, Maria Grazia Morgese, et al.
Pharmacological Research|October 11, 2023
Sex-oriented perspectives in immunopharmacologyAndrea Cignarella, Elisabetta Vegeto, Chiara Bolego, et al.
Current Pharmaceutical Biotechnology|February 9, 2017
Personalized Medicine in the Paediatric Population: The Balance Between Pharmacogenetic Progress and BioethicsStefania Schiavone, Margherita Neri, Cristoforo Pomara, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Psychopharmacology|August 18, 2016
Involvement of the NADPH Oxidase NOX2-Derived Brain Oxidative Stress in an Unusual Fatal Case of Cocaine-Related Neurotoxicity Associated With Excited Delirium SyndromeStefania Schiavone, Irene Riezzo, Emanuela Turillazzi, et al.
Scientific Reports|August 20, 2017
The NADPH oxidase NOX2 mediates loss of parvalbumin interneurons in traumatic brain injury: human autoptic immunohistochemical evidenceStefania Schiavone, Margherita Neri, Luigia Trabace, et al.
Molecules (Basel, Switzerland)|August 7, 2021
The Therapeutic Potential of Celastrol in Central Nervous System Disorders: Highlights from In Vitro and In Vivo ApproachesStefania Schiavone, Maria Grazia Morgese, Paolo Tucci, et al.
Molecules (Basel, Switzerland)|November 8, 2019
Early Celastrol Administration Prevents Ketamine-Induced Psychotic-Like Behavioral Dysfunctions, Oxidative Stress and IL-10 Reduction in The Cerebellum of Adult MiceStefania Schiavone, Paolo Tucci, Luigia Trabace, et al.
Antioxidants & Redox Signaling|July 4, 2012
Severe life stress and oxidative stress in the brain: from animal models to human pathologyStefania Schiavone, Vincent Jaquet, Luigia Trabace, et al.
CNS Drug Reviews|June 19, 2002
CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitorLuigia Trabace, Tommaso Cassano, Antonia Loverre, et al.
International Review of Neurobiology|July 18, 2009
Developmental exposure to cannabinoids causes subtle and enduring neurofunctional alterationsPatrizia Campolongo, Viviana Trezza, Maura Palmery, et al.
Neuroscience Research|December 24, 2011
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated ratsAlex Martinez, Teresa Macheda, Maria Grazia Morgese, et al.
Pharmacological Research|October 11, 2023
Sex-oriented perspectives in immunopharmacologyAndrea Cignarella, Elisabetta Vegeto, Chiara Bolego, et al.
Current Pharmaceutical Biotechnology|February 9, 2017
Personalized Medicine in the Paediatric Population: The Balance Between Pharmacogenetic Progress and BioethicsStefania Schiavone, Margherita Neri, Cristoforo Pomara, et al.
Pageof 10